ADMA

Companies
NASDAQ
Adma Biologics Inc.
Health Care
Price Chart
Overview

About ADMA

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Market Cap
$2.4B
Volume
50.6M
Avg. Volume
61.9M
P/E Ratio
24.98611
Dividend Yield
0.00%
Employees
463.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.01
Moderate Correlation
Volatility
High (0.62)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ADMA.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ADMA shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$2.4B
Volume50.6M
P/E Ratio24.99
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 4, 2025

PortfolioPilot Analysis

Get AI-powered insights on how ADMA fits into your investment strategy and portfolio diversification.

Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025